Automated PKD Organoid Screening for Cyst-Shrinking Compounds
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current high-throughput screening (HTS) platforms for organoids, particularly those derived from human pluripotent stem cells (hPSCs), face challenges in automation and miniaturization due to complex three-dimensional growth conditions and lengthy differentiation steps, limiting their application in modeling complex diseases like Polycystic Kidney Disease (PKD) and identifying therapeutic agents.
Innovation Solution
A method involving the use of myosin II activators, such as thiadiazinone compounds, to prevent or shrink cysts in kidney organoids, combined with a high-throughput screening platform that automates the generation and testing of therapeutic compound candidates on phenotypic organoid models, utilizing liquid handling robots and single-cell RNA-seq for analysis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If human pluripotent stem cells are used to derive organoids for high-throughput screening, then the ability to model complex diseases and test immunocompatible therapies is improved, but the complexity of three-dimensional growth conditions and lengthy differentiation steps increases automation difficulty
Solution Approach 1:
The patent segments the organoid differentiation process into discrete, automated steps that can be performed in high-throughput format. The system divides the complex differentiation protocol into manageable stages including cell plating, media addition, and automated imaging, allowing each step to be controlled by liquid handling robots and automated systems.
Solution Approach 2:
The patent introduces automated liquid handling systems and robotic platforms as intermediaries between the researcher and the complex organoid culture system. These automated systems mediate the delivery of growth factors, differentiation media, and compounds to organoids, eliminating manual intervention while maintaining the complex three-dimensional culture conditions required for hPSC-derived organoids.
2Extent of automation
If traditional cell culture methods are used for high-throughput screening, then automation and miniaturization are easier to implement, but the capacity to model complex tissue phenotypes is restricted
Solution Approach 1:
The patent creates simplified copies of complex organoid structures that can be maintained in high-throughput format. The system uses automated liquid handling to replicate organoid culture conditions across thousands of wells, creating miniature versions of complex three-dimensional cultures that retain disease-relevant phenotypes while being compatible with automated screening platforms.
Solution Approach 2:
The patent modifies culture parameters to enable automation while preserving organoid functionality. This includes optimizing well plate formats, media composition, and incubation conditions to allow automated liquid handling robots to deliver precise volumes of growth factors and differentiation media, thereby maintaining complex tissue phenotypes in an automated high-throughput environment.
3Adaptability or versatility
If lengthy stepwise differentiation steps are used to generate hPSC-derived organoids, then the ability to generate diverse organ types is improved, but the time required for high-throughput screening increases
Solution Approach 1:
The patent performs preliminary differentiation steps before high-throughput screening to reduce the time required during actual screening. The system pre-differentiates hPSCs into progenitor cells or early-stage organoids that can then be rapidly tested with compounds in a high-throughput format, separating the time-intensive differentiation phase from the screening phase.
Solution Approach 2:
The patent implements continuous differentiation protocols that can proceed uninterrupted during the screening process. The system uses automated liquid handling to continuously supply differentiation media and growth factors to organoids throughout the differentiation process, eliminating manual intervention delays and maintaining continuous useful action from differentiation through screening.
4Measurement precision
If special processing for immunofluorescence is used to analyze organoids, then the ability to detect specific cellular markers is improved, but the complexity of automation and miniaturization increases
Solution Approach 1:
The patent extracts the immunofluorescence processing steps from the main high-throughput screening workflow and performs them as separate, optimized operations. The system automates antibody incubation, washing, and imaging steps using robotic liquid handlers, separating the complex immunofluorescence protocol into discrete automated operations that can be applied to multiple organoids simultaneously without increasing overall system complexity.
Data Source
AI summary
Methods for testing the effects of therapeutic compound candidates on a phenotypic organoid model is provided. Such a method includes steps of generating the phenotypic organoid model on a high throughput screening platform, treating the organoid with a therapeutic compound candidate, and testing one or more effects resulting from treatment with each of the therapeutic compound candidates. The testing method that has led to identification of a method for treating or preventing cysts is provided. That method may include contacting a population of cells with an inotrope, wherein the inotrope prevents cyst formation, shrinks existing cysts, or both. That method may be used to treat cystogenic diseases or conditions such as Polycystic Kidney Disease (PKD).